Grid Therapeutics is pioneering innovative cancer therapies by leveraging the human immune system, specifically through the development of novel tumor-specific therapeutic antibodies derived from single human B cells. Their advanced high-throughput single B cell culturing platform allows for the rapid discovery and generation of fully human-derived, tumor-targeted recombinant antibodies. This approach is designed to be efficient and cost-effective, enabling the simultaneous identification of multiple biologically relevant targets and antibodies without relying on prior knowledge of the target proteins. The company’s research emphasizes maximizing the discovery of antibodies with potent anti-tumor activity, facilitating a swift transition from research findings to clinically relevant therapies.

One of the key products in Grid Therapeutics' pipeline is GT103, a fully human monoclonal antibody targeting a unique epitope on the complement factor H (CFH) protein, which plays a role in tumor cell protection. This antibody was developed from B cells isolated from lung cancer patients who exhibited exceptional outcomes, specifically those who did not develop metastasis. GT103 has shown promise in preclinical models by inhibiting tumor growth and modulating the immune response, leading to a reduction in immune-suppressive cells within the tumor environment. The FDA has granted an Investigational New Drug (IND) application for GT103, allowing Grid Therapeutics to initiate a Phase I clinical trial in advanced cancer patients, with plans for further development across multiple cancer types.

United States

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.

Grid Therapeutics

Company Details